NASDAQ:MESO Mesoblast (MESO) Stock Price, News & Analysis → Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad) Free MESO Stock Alerts $7.96 -0.05 (-0.62%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$7.65▼$8.3950-Day Range$1.97▼$8.0152-Week Range$1.61▼$10.24Volume336,942 shsAverage Volume1.67 million shsMarket Capitalization$908.30 millionP/E RatioN/ADividend YieldN/APrice Target$13.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Mesoblast alerts: Email Address Mesoblast MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside71.8% Upside$13.67 Price TargetShort InterestHealthy0.63% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.71) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 starsMedical Sector524th out of 903 stocksBiological Products, Except Diagnostic Industry85th out of 153 stocks 3.1 Analyst's Opinion Consensus RatingMesoblast has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageMesoblast has received no research coverage in the past 90 days.Read more about Mesoblast's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.63% of the outstanding shares of Mesoblast have been sold short.Short Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mesoblast has recently decreased by 69.40%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MESO. Previous Next 1.8 News and Social Media Coverage News SentimentMesoblast has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Mesoblast this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for MESO on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is a decrease of -58% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock.Percentage Held by Insiders18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.43% of the stock of Mesoblast is held by institutions.Read more about Mesoblast's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mesoblast are expected to grow in the coming year, from ($0.71) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mesoblast is -7.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mesoblast is -7.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMesoblast has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Mesoblast's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Smallcaps DailyThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySee how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.Click to read About Mesoblast Stock (NASDAQ:MESO)Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Read More MESO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MESO Stock News HeadlinesMay 7, 2024 | americanbankingnews.comMesoblast Limited (NASDAQ:MESO) Receives Consensus Rating of "Hold" from AnalystsMay 3, 2024 | msn.comIf you invested $8,000 in Mesoblast shares at the beginning of 2024, guess how much you'd have now!May 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.May 2, 2024 | msn.comASX 200 closes down 1.23 per cent on WednesdayMay 1, 2024 | msn.comAustralia stocks lower at close of trade; S&P/ASX 200 down 1.23%May 1, 2024 | americanbankingnews.comMesoblast (NASDAQ:MESO) Upgraded to Hold at StockNews.comApril 30, 2024 | msn.comYen falls after suspected intervention on Monday, eyes on FedApril 30, 2024 | msn.comWhy is the Mesoblast share price taking a dive on Tuesday?May 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.April 29, 2024 | globenewswire.comAppendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024April 29, 2024 | msn.comSoft landing remains within reach as consumer spending spree set for breather: UBSApril 29, 2024 | msn.comStablecoin Tether is losing market share - reportApril 29, 2024 | msn.comUS Dollar Uptrend on Thin Ice as Fed Takes Center Stage This WeekApril 16, 2024 | msn.comInsiders are buying Mesoblast and these ASX sharesApril 10, 2024 | seekingalpha.comMesoblast Limited: Back From The DeadApril 5, 2024 | msn.comWhy is everyone talking about Mesoblast shares?April 4, 2024 | finance.yahoo.comSpinal Fusion Pipeline Report 2024, Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key CompaniesApril 3, 2024 | msn.comFed members back cutting rates this year, but need confidence inflation slowingApril 3, 2024 | investorplace.comFeeling Bold? 3 Aggressive Plays to 10X Your Returns by 2025April 3, 2024 | au.investing.comTop ASX Stocks for this MonthApril 2, 2024 | fool.com.auMesoblast share price dumps 10% as excitement simmers on FDA submissionApril 2, 2024 | au.investing.comWhat is next for Tesla stock after soft Q1 sales reportApril 1, 2024 | fool.com.auBlast off! Mesoblast share price surging 60%March 31, 2024 | fool.com.auTop ASX shares to buy in April 2024March 29, 2024 | finance.yahoo.comAohua receives Endoscopy Award at Healthcare Asia Medtech Awards 2024March 28, 2024 | morningstar.comMesoblast Ltd LWBMarch 27, 2024 | afr.comASX retreats ahead of CPI; Mesoblast soars 45pcSee More Headlines Receive MESO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/30/2023Today5/07/2024Next Earnings (Estimated)5/23/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:MESO Previous SymbolOTCMKTS:MBLTY CUSIPN/A CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036Fax61-3-9639-6030Employees83Year FoundedN/APrice Target and Rating Average Stock Price Target$13.67 High Stock Price Target$34.00 Low Stock Price Target$3.00 Potential Upside/Downside+71.8%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.21 Current Ratio2.71 Quick RatioN/A Sales & Book Value Annual Sales$7.50 million Price / Sales121.11 Cash FlowN/A Price / Cash FlowN/A Book Value$6.16 per share Price / Book1.29Miscellaneous Outstanding Shares114,180,000Free Float92,713,000Market Cap$908.30 million OptionableOptionable Beta3.45 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Silviu Itescu FACP (Age 67)FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Comp: $738.74kDr. Eric A. Rose M.D. (Age 73)Chief Medical Officer & Executive Director Comp: $625.46kMr. Andrew Chaponnel B.Com.Interim Chief Finance OfficerMr. Peter T. Howard B.Sc. (Age 56)L.L.B., LLB (Hons), General Counsel & Corporate Executive Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersMr. Michael Schuster BSc (Age 47)M.B.A., MS, Head of Pharma Partnering Ms. Geraldine Storton B.Sc.M.B.A., MMS, Head of Regulatory Affairs & Quality ManagementMr. Justin Horst B.S.Head of ManufacturingMs. Niva Sivakumar B.Com.L.L.B., Joint Company SecretaryMr. Paul Hughes BPHARMJoint Company SecretaryMore ExecutivesKey CompetitorsREGENXBIONASDAQ:RGNXCARGO TherapeuticsNASDAQ:CRGXImmaticsNASDAQ:IMTXHilleVaxNASDAQ:HLVXBioCryst PharmaceuticalsNASDAQ:BCRXView All CompetitorsInstitutional OwnershipChase Investment Counsel CorpBought 59,600 shares on 5/2/2024Ownership: 0.052%Penbrook Management LLCSold 150,175 shares on 4/18/2024Ownership: 0.110%Chapin Davis Inc.Sold 7,000 shares on 4/18/2024Ownership: 0.009%Affinity Asset Advisors LLCSold 400,000 shares on 2/13/2024Ownership: 0.000%View All Institutional Transactions MESO Stock Analysis - Frequently Asked Questions Should I buy or sell Mesoblast stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares. View MESO analyst ratings or view top-rated stocks. What is Mesoblast's stock price target for 2024? 6 equities research analysts have issued 12 month price targets for Mesoblast's shares. Their MESO share price targets range from $3.00 to $34.00. On average, they predict the company's stock price to reach $13.67 in the next year. This suggests a possible upside of 71.8% from the stock's current price. View analysts price targets for MESO or view top-rated stocks among Wall Street analysts. How have MESO shares performed in 2024? Mesoblast's stock was trading at $2.20 at the start of the year. Since then, MESO shares have increased by 261.6% and is now trading at $7.9550. View the best growth stocks for 2024 here. Are investors shorting Mesoblast? Mesoblast saw a decrease in short interest in April. As of April 15th, there was short interest totaling 716,100 shares, a decrease of 69.4% from the March 31st total of 2,340,000 shares. Based on an average daily volume of 2,160,000 shares, the days-to-cover ratio is currently 0.3 days. View Mesoblast's Short Interest. When is Mesoblast's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024. View our MESO earnings forecast. How were Mesoblast's earnings last quarter? Mesoblast Limited (NASDAQ:MESO) issued its quarterly earnings results on Wednesday, August, 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06. The business had revenue of $2.14 million for the quarter, compared to the consensus estimate of $2 million. When did Mesoblast's stock split? Mesoblast's stock reverse split before market open on Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV). When did Mesoblast IPO? Mesoblast (MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers. Who are Mesoblast's major shareholders? Mesoblast's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Penbrook Management LLC (0.11%), Chase Investment Counsel Corp (0.05%) and Chapin Davis Inc. (0.01%). How do I buy shares of Mesoblast? Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MESO) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorGold Set to EXPLODE!Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI “wealth window” is closing June 25thParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsStock-Picking AI Predicts #1 Stock of 2024AltimetryElon Musk Secret Crypto Plot ExposedCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.